138 related articles for article (PubMed ID: 36870603)
21. Test trial of spike-in immunoglobulin heavy-chain (IGH) controls for next generation sequencing quantification of minimal residual disease in acute lymphoblastic leukaemia.
Giusti GNN; Jotta PY; Lopes CO; Ganazza MA; de Azevedo AC; Brandalise SR; Meidanis J; Yunes JA
Br J Haematol; 2020 May; 189(4):e150-e154. PubMed ID: 32187384
[No Abstract] [Full Text] [Related]
22. Next-Generation Sequencing in Adult B Cell Acute Lymphoblastic Leukemia Patients.
Sala Torra O; Othus M; Williamson DW; Wood B; Kirsch I; Robins H; Beppu L; O'Donnell MR; Forman SJ; Appelbaum FR; Radich JP
Biol Blood Marrow Transplant; 2017 Apr; 23(4):691-696. PubMed ID: 28062215
[TBL] [Abstract][Full Text] [Related]
23. Measurable residual disease in acute lymphoblastic leukemia: How low is low enough?
Logan AC
Best Pract Res Clin Haematol; 2022 Dec; 35(4):101407. PubMed ID: 36517126
[TBL] [Abstract][Full Text] [Related]
24. Establishment and validation of a standard protocol for the detection of minimal residual disease in B lineage childhood acute lymphoblastic leukemia by flow cytometry in a multi-center setting.
Irving J; Jesson J; Virgo P; Case M; Minto L; Eyre L; Noel N; Johansson U; Macey M; Knotts L; Helliwell M; Davies P; Whitby L; Barnett D; Hancock J; Goulden N; Lawson S; ;
Haematologica; 2009 Jun; 94(6):870-4. PubMed ID: 19377076
[TBL] [Abstract][Full Text] [Related]
25. Monitoring of minimal residual disease in early T-cell precursor acute lymphoblastic leukaemia by next-generation sequencing.
Pan X; Nariai N; Fukuhara N; Saito S; Sato Y; Katsuoka F; Kojima K; Kuroki Y; Danjoh I; Saito R; Hasegawa S; Okitsu Y; Kondo A; Onishi Y; Nagami F; Kiyomoto H; Hozawa A; Fuse N; Nagasaki M; Shimizu R; Yasuda J; Harigae H; Yamamoto M
Br J Haematol; 2017 Jan; 176(2):318-321. PubMed ID: 26822323
[No Abstract] [Full Text] [Related]
26. Application of Next-Generation Sequencing-Based Mutational Profiling in Acute Lymphoblastic Leukemia.
Aleem A; Haque AR; Roloff GW; Griffiths EA
Curr Hematol Malig Rep; 2021 Oct; 16(5):394-404. PubMed ID: 34613552
[TBL] [Abstract][Full Text] [Related]
27. Clinical impact of low-burden BCR-ABL1 mutations detectable by amplicon deep sequencing in Philadelphia-positive acute lymphoblastic leukemia patients.
Soverini S; De Benedittis C; Papayannidis C; Polakova KM; Venturi C; Russo D; Bresciani P; Iurlo A; Mancini M; Vitale A; Chiaretti S; Foà R; Abruzzese E; Sorà F; Kohlmann A; Haferlach T; Baccarani M; Cavo M; Martinelli G
Leukemia; 2016 Jul; 30(7):1615-9. PubMed ID: 26867670
[No Abstract] [Full Text] [Related]
28. Targeted RNA-sequencing for the quantification of measurable residual disease in acute myeloid leukemia.
Dillon LW; Hayati S; Roloff GW; Tunc I; Pirooznia M; Mitrofanova A; Hourigan CS
Haematologica; 2019 Feb; 104(2):297-304. PubMed ID: 30171026
[TBL] [Abstract][Full Text] [Related]
29. Minimal Residual Disease Detection in Acute Lymphoblastic Leukemia.
Kruse A; Abdel-Azim N; Kim HN; Ruan Y; Phan V; Ogana H; Wang W; Lee R; Gang EJ; Khazal S; Kim YM
Int J Mol Sci; 2020 Feb; 21(3):. PubMed ID: 32033444
[TBL] [Abstract][Full Text] [Related]
30. A clinical perspective on immunoglobulin heavy chain clonal heterogeneity in B cell acute lymphoblastic leukemia.
Fries C; Burack WR
Leuk Res; 2018 Dec; 75():15-22. PubMed ID: 30445235
[TBL] [Abstract][Full Text] [Related]
31. Minimal residual disease detection by mutation-specific droplet digital PCR for leukemia/lymphoma.
Shirai R; Osumi T; Keino D; Nakabayashi K; Uchiyama T; Sekiguchi M; Hiwatari M; Yoshida M; Yoshida K; Yamada Y; Tomizawa D; Takae S; Kiyokawa N; Matsumoto K; Yoshioka T; Hata K; Hori T; Suzuki N; Kato M
Int J Hematol; 2023 Jun; 117(6):910-918. PubMed ID: 36867356
[TBL] [Abstract][Full Text] [Related]
32. ClonoSEQ assay for the detection of lymphoid malignancies.
Monter A; Nomdedéu JF
Expert Rev Mol Diagn; 2019 Jul; 19(7):571-578. PubMed ID: 31179776
[No Abstract] [Full Text] [Related]
33. Immunoglobulin and T cell receptor gene high-throughput sequencing quantifies minimal residual disease in acute lymphoblastic leukemia and predicts post-transplantation relapse and survival.
Logan AC; Vashi N; Faham M; Carlton V; Kong K; Buño I; Zheng J; Moorhead M; Klinger M; Zhang B; Waqar A; Zehnder JL; Miklos DB
Biol Blood Marrow Transplant; 2014 Sep; 20(9):1307-13. PubMed ID: 24769317
[TBL] [Abstract][Full Text] [Related]
34. Next-generation sequencing of PTEN mutations for monitoring minimal residual disease in T-cell acute lymphoblastic leukemia.
Germano G; Valsecchi MG; Buldini B; Cazzaniga G; Zanon C; Silvestri D; Te Kronnie G; Basso G; Paganin M
Pediatr Blood Cancer; 2020 Jan; 67(1):e28025. PubMed ID: 31571345
[TBL] [Abstract][Full Text] [Related]
35. Next-generation antigen receptor sequencing of paired diagnosis and relapse samples of B-cell acute lymphoblastic leukemia: Clonal evolution and implications for minimal residual disease target selection.
Theunissen PMJ; de Bie M; van Zessen D; de Haas V; Stubbs AP; van der Velden VHJ
Leuk Res; 2019 Jan; 76():98-104. PubMed ID: 30389174
[TBL] [Abstract][Full Text] [Related]
36. Considerations for monitoring minimal residual disease using immunoglobulin clonality in patients with precursor B-cell lymphoblastic leukemia.
Jo I; Chung NG; Lee S; Kwon A; Kim J; Choi H; Jang W; Kim S; Lee JW; Yoon JH; Cho B; Han K; Kim Y; Kim M
Clin Chim Acta; 2019 Jan; 488():81-89. PubMed ID: 30389459
[TBL] [Abstract][Full Text] [Related]
37. Immunoglobulin and T-cell receptor gene rearrangements as PCR-based targets are stable markers for monitoring minimal residual disease in acute lymphoblastic leukemia after stem cell transplantation.
Kreyenberg H; Eckert C; Yarkin Y; Reising M; Willasch A; Handgretinger R; Kremens B; von Stackelberg A; Henze G; Klingebiel T; Bader P
Leukemia; 2009 Jul; 23(7):1355-8. PubMed ID: 19357703
[No Abstract] [Full Text] [Related]
38. Next-Generation Sequencing Technology to Identify Minimal Residual Disease in Lymphoid Malignancies.
Kotrova M; Darzentas N; Pott C; Brüggemann M;
Methods Mol Biol; 2021; 2185():95-111. PubMed ID: 33165845
[TBL] [Abstract][Full Text] [Related]
39. Quantitative assessment of minimal residual disease in childhood lymphoid malignancies using an allele-specific oligonucleotide real-time quantitative polymerase chain reaction.
Tarusawa M; Yashima A; Endo M; Maesawa C
Int J Hematol; 2002 Feb; 75(2):166-73. PubMed ID: 11939263
[TBL] [Abstract][Full Text] [Related]
40. A simplified minimal residual disease polymerase chain reaction method at early treatment points can stratify children with acute lymphoblastic leukemia into good and poor outcome groups.
Scrideli CA; Assumpção JG; Ganazza MA; Araújo M; Toledo SR; Lee ML; Delbuono E; Petrilli AS; Queiróz RP; Biondi A; Viana MB; Yunes JA; Brandalise SR; Tone LG
Haematologica; 2009 Jun; 94(6):781-9. PubMed ID: 19483156
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]